A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients

Exclusion Criteria

• •Patients eligible for inclusion in this study must meet all of the following criteria:
• •5. ≥ 18 years of age.
• •6. Diagnosed with CSU by an HCP.
• •7. Have received a prescription for remibrutinib or dupilumab and are expected to initiate treatment.
• •8. Have access to an electronic device with internet capabilities.
• •9. Able to read and understand English.
• •10. Willing and able to provide consent for study participation.
• •Patients will be excluded if they meet any of the following criteria:
• •1. Unable to procure remibrutinib or dupilumab (through samples, commercially or patient assistance program).
• •2. Exposure to oral corticosteroid treatment in 14 days prior to consent.
• •3. Exposure to oral corticosteroid treatment in 14 days prior to initiating treatment with remibrutinib or dupilumab.
• •4. Prior participation in a remibrutinib or dupilumab clinical trial.
• •5. Cognitive impairment that impacts the patient's ability to participate.